• Mashup Score: 1
    Neoadjuvant Atezolizumab in Stage IB/IIIB Resectable Lung Cancer - 3 year(s) ago

    Neoadjuvant atezolizumab was well-tolerated by patients with stage IB-IIIB lung cancer, according to the primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study. “The LCMC3 study is a unique trial in that it is the largest monotherapy trial of checkpoint inhibition in resectable non-small cell lung cancer (NSCLC),” noted Jay M. Lee, MD, from the UCLA Medical Center, who presented…

    Source: know.lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      Neoadjuvant Atezolizumab in Stage IB/IIIB Resectable #LungCancer https://t.co/aiQh4FUlgl #cancertreatment #medtwitter via @UCLAHealth https://t.co/ADIRSdajil

  • Mashup Score: 7
    AACR 2021: Nivolumab/Chemo Significantly Boosts NSCLC Response - 3 year(s) ago

    Nivolumab plus chemotherapy significantly improved pathological complete response rates compared to chemotherapy alone in patients with resectable stage Ib-IIIa non-small cell lung cancer (NSCLC), according to findings presented at the AACR Annual Meeting 2021.

    Source: know.lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      #AACR21 Update: Nivolumab/Chemo Significantly Boosts NSCLC Response https://t.co/C5zoY0aD92 #lungcancer #medtwitter #cancertreatment via @FordePatrick @hopkinskimmel https://t.co/fCWSQk0Dvb

  • Mashup Score: 1
    Final Results From the International Tailored Chemotherapy Adjuvant Trial - 3 year(s) ago

    Findings from a Phase III study found that evaluating mRNA expression of selected genes to tailor adjuvant chemotherapy did not improve survival outcomes among patients with resected stage II-III non-small cell lung cancer (NSCLC). Final results from the International Tailored Chemotherapy Adjuvant trial (ITACA) were presented at the 2021 International Association for the Study of Lung Cancer…

    Source: know.lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      From our new #LungCancer Resource Center: Final Results From the International Tailored Chemotherapy Adjuvant Trial https://t.co/F65eeuBhle #medtwitter #cancertreatment #oncology https://t.co/R40bE2tN2w

  • Mashup Score: 4
    Sotorasib Shows Durable Response in KRAS p.G12C-Mutated NSCLC - 3 year(s) ago

    The Phase II CodeBreaK 100 trial demonstrated the durable clinical benefit and safety of sotorasib for patients with non-small cell lung cancer (NSCLC) who harbor KRAS p.G12C mutations. Study author Bob Li, MD, PhD, MPH, of Memorial Sloan Kettering Cancer Center, presented these findings at the International Association for the Study of Lung Cancer World Conference on Lung Cancer (Abstract…

    Source: know.lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      ICYMI: Sotorasib Shows Durable Response in KRAS p.G12C-Mutated Non-Small Cell Lung Cancer https://t.co/EMPnbQ0TDV #cancertreatment #medtwitter #LCSM via @sloan_kettering https://t.co/GRVIWRd9P1

  • Mashup Score: 5
    AACR 2021: Nivolumab/Chemo Significantly Boosts NSCLC Response - 3 year(s) ago

    Nivolumab plus chemotherapy significantly improved pathological complete response rates compared to chemotherapy alone in patients with resectable stage Ib-IIIa non-small cell lung cancer (NSCLC), according to findings presented at the AACR Annual Meeting 2021.

    Source: know.lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      #AACR21 Update: Nivolumab/Chemo Significantly Boosts NSCLC Response https://t.co/C5zoY0aD92 #lungcancer #medtwitter #cancertreatment via @FordePatrick @hopkinskimmel https://t.co/5Mq6ClMPM0

  • Mashup Score: 1
    Exploring Prescribing Patterns in Lung Cancer Patients at the End of Life - 3 year(s) ago

    A recent study found that more than 10 percent of lung cancer patients received some treatment in the last 30 days of life, according to data presented at the NCCN 2021 Virtual Annual Conference (Abstract EPR21-040). The researchers noted that this suggests “that a substantial number of patients are still being treated shortly before their death, a practice that warrants further exploration.”

    Source: know.lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      Hot off the press! Exploring Prescribing Patterns in #LungCancer Patients at the End of Life https://t.co/f5AaX8vD85 #cancertreatment #healthcare via @HopkinsMedicine https://t.co/hD2ZEvJ0wz

Load More